Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Lieve KV
  • van der Werf C
  • Kallas D
  • Denjoy I
  • Bos JM
  • Aiba T
  • Behr ER
  • van den Berg MP
  • Bergeman AT
  • Blom NA
  • Borggrefe M
  • Brugada R
  • Carrillo Mora LM
  • Chorin E
  • Crotti L
  • Davis A
  • Drago F
  • Dusi V
  • Extramiana F
  • Franciosi S
  • Giudicessi JR
  • González Llopis FÁ
  • Haugaa KH
  • van den Heuvel F
  • Horie M
  • Ingles J
  • Kammeraad J
  • Kannankeril PJ
  • Khan HR
  • Krahn AD
  • MacIntyre C
  • Maltret A
  • Marjamaa A
  • Ohno S
  • Peltenburg PJ
  • Perez GJ
  • Probst V
  • Roberts JD
  • Robyns T
  • Rootwelt-Norberg C
  • Roses I Noguer F
  • Roston TM
  • Rydberg A
  • Sacher F
  • Sarquella-Brugada G
  • Schwartz PJ
  • Semsarian C
  • Shimizu W
  • Starling L
  • Sumitomo N
  • Skinner JR
  • Tavacova T
  • Tfelt-Hansen J
  • Till JA
  • Yap SC
  • Wada Y
  • Wangüemert F
  • Ackerman MJ
  • Leenhardt A
  • Sanatani S
  • Tanck MW
  • Wilde AA

Grupos

Abstract

BACKGROUND AND AIMS: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for potentially life-threatening arrhythmic events (AEs) even while treated with ß-blockers. The aim was to develop a model for individualized prediction of AEs in patients with RYR2-mediated CPVT on ß-blocker monotherapy. METHODS: The derivation and independent validation cohorts included 743 and 129 patients, respectively. AEs were defined as arrhythmic syncope, appropriate implantable cardioverter-defibrillator shock, sudden cardiac arrest (SCA), and sudden cardiac death. Near-fatal or fatal AEs (nf/fAEs) included all AEs except for arrhythmic syncope. Prediction models using Cox regression were developed and internally and externally validated. RESULTS: A total of 102 (13.7%) patients in the derivation cohort and 24 (18.6%) patients in the validation cohort experienced =1 AE over a median follow-up of 5.1 [interquartile range (IQR), 7.7] and 2.4 (IQR, 4.4) years, respectively. Predictors of AE were arrhythmic syncope or SCA prior to diagnosis and age at ß-blocker initiation. In the derivation and validation cohorts, the optimism-corrected C-indices of the models for AE were 0.67 [95% confidence interval (CI) 0.62-0.72] and 0.59 (95% CI 0.48-0.71), respectively. For nf/fAEs, ventricular arrhythmia severity before ß-blocker initiation was a fourth independent predictor, and C-indices of the models in the derivation and validation cohorts were 0.74 (95% CI 0.68-0.80) and 0.60 (95% CI 0.47-0.72), respectively. In the derivation cohort, calibration slopes were 1.00 (95% CI 0.59-1.41) for AE and 1.00 (95% CI 0.69-1.32) for nf/fAE. CONCLUSIONS: These externally validated risk prediction models using clinical parameters accurately distinguished CPVT patients on ß-blocker monotherapy at low and high risk for future AEs while treated with ß-blockers. These models provide guidance for implementation of clinical management therapies to prevent AEs in patients with CPVT.

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Datos de la publicación

ISSN/ISSNe:
0195-668X, 1522-9645

EUROPEAN HEART JOURNAL  OXFORD UNIV PRESS

Tipo:
Article
Páginas:
4606-4617
PubMed:
41416846
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
4,118 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 5

Citas Recibidas en Scopus: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Catecholaminergic polymorphic ventricular tachycardia; Risk stratification; Sudden cardiac death; Ventricular arrhythmias; ß-Blockers

Cita

Compartir